A new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cells or NK cells) to kill myeloma. Learn more about this emerging therapy from Dr. Shaji Kumar on this fascinating program. 

Thanks to our episode sponsor, Takeda Oncology

Join Dr. Dan Vogl and Dr. Yulia Nefedova to understand more about a new oral treatment for multiple myeloma called tasquinimod. This is a treatment that targets the tumor microenvironment by targeting myeloid-derived suppressor cells (MDSCs). MDSCs are a variety of cells that expand during cancer, inflammation and infection, and can suppress T-cell responses. They can stop myeloma killing-immune cells and at the same time form new tumor blood vessels that help myeloma spread in the body. The researchers are hopeful that tasquinimod will promote anti-tumor immune activity . 

The treament is being developed by a Swedish company called Active Biotech and tasquinimod is now being tested in combination with standard myeloma therapies like lenalidomide, ixazomib and dex. 

New treatments like these could be used in patients who have relapsed after standard myeloma treatment like daratumumab and could help alter the microenvironment that is causing myeloma relapse.

Thanks to our episode sponsor, Bristol Myers Squibb

Join Dr. Dan Vogl and Dr. Yulia Nefedova to understand more about a new oral treatment for multiple myeloma called tasquinimod. This is a treatment that targets the tumor microenvironment by targeting myeloid-derived suppressor cells (MDSCs). MDSCs are a variety of cells that expand during cancer, inflammation and infection, and can suppress T-cell responses. They can stop myeloma killing-immune cells and at the same time form new tumor blood vessels that help myeloma spread in the body. The researchers are hopeful that tasquinimod will promote anti-tumor immune activity . 

The treament is being developed by a Swedish company called Active Biotech and tasquinimod is now being tested in combination with standard myeloma therapies like lenalidomide, ixazomib and dex. 

New treatments like these could be used in patients who have relapsed after standard myeloma treatment like daratumumab and could help alter the microenvironment that is causing myeloma relapse.

Thanks to our episode sponsor, Bristol Myers Squibb

Smoldering myeloma is a precursor condition for the blood cancer multiple myeloma. There is hot debate about when and how to treat this precursor condition. Do you treat it like regular myeloma? Do you try to prevent progression? And if so, with which therapies? Dr. Elisabet Manasanch of the MD Anderson Cancer Center provides an update on treatment in smoldering myeloma and smoldering myeloma clinical trial designs that seek to determine the very best approach.  

Thanks to our episode sponsor, Bristol Myers Squibb

Smoldering myeloma is a precursor condition for the blood cancer multiple myeloma. There is hot debate about when and how to treat this precursor condition. Do you treat it like regular myeloma? Do you try to prevent progression? And if so, with which therapies? Dr. Elisabet Manasanch of the MD Anderson Cancer Center provides an update on treatment in smoldering myeloma and smoldering myeloma clinical trial designs that seek to determine the very best approach.  

Thanks to our episode sponsor, Bristol Myers Squibb

All cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for patients on BLENREP. Learn what keratopathy is, how care is coordinated between the myeloma doctor and the eye doctor, and what patients should know about keratopathy before starting on this therapy. 

Thanks to our episode sponsor, Takeda Oncology

All cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for patients on BLENREP. Learn what keratopathy is, how care is coordinated between the myeloma doctor and the eye doctor, and what patients should know about keratopathy before starting on this therapy. 

Thanks to our episode sponsor, Takeda Oncology

Myeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy following stem cell transplant. Is earlier use better? Should they be "saved" for later? When should patients consider using the monoclonal antibodies as maintenance therapy with or without traditional drugs like lenalidomide? Dr. Voorhees will help answer these very practical questions for the myeloma community.

Thanks to our episode sponsor, Karyopharm Therapeutics.

Myeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy following stem cell transplant. Is earlier use better? Should they be "saved" for later? When should patients consider using the monoclonal antibodies as maintenance therapy with or without traditional drugs like lenalidomide? Dr. Voorhees will help answer these very practical questions for the myeloma community.

Thanks to our episode sponsor, Karyopharm Therapeutics.

AL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join HealthTree Podcast for Multiple Myeloma by HealthTree to hear from Sascha Tuchman, MD of the University of North Carolina at Chapel Hill as he shares amyloidosis symptoms, treatments and open clinical trials. 

Thanks to our episode sponsor, Takeda Oncology